Skip to main content

Table 1 Admission reason and patients’ characteristics

From: Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

 

IVIG (n = 19)

Placebo (n = 19)

P-value

Admission reason

Number of patients

Respiratory failure

7

8

1.00

Cardiopulmonary resuscitation

1

2

1.00

Sepsis/septic shock

9

8

1.00

Cardiogenic shock

1

1

1.00

Coma

1

0

1.00

Age (years)

61 ± 11

66 ± 12

0.18

Gender (female/male)

(7/12)

(10/9)

0.52

BMI (kg/m2)

28 ± 5

28 ± 6

0.94

SOFA score

11 ± 4

11 ± 5

0.88

APACHE III score

96 ± 28

96 ± 24

0.99

Mortality on Day 14 (non-survivors (%))

3 (16%)

3 (16%)

1.00

Mortality on Day 28 (non-survivors (%))

5 (26%)

6 (32%)

1.00

Length of ICU stay (days)

30 ± 16

27 ± 13

0.66

CIP score on Day 0

2.6 ± 1.5

2.0 ± 1.3

0.26

CIM score on Day 0

1.1 ± 0.8

1.4 ± 0.8

0.27

CIPNM severity sum score on Day 0

3.6 ± 1.8

3.4 ± 1.5

0.71

C-reactive protein (mg/dL) on Day 0

13 ± 11

13 ± 8

0.99

Fibrinogen (mg/dL) on Day 0

462 ± 186

563 ± 192

0.11

Leukocytes (G/L) on Day 0

19.4 ± 10.3

18.6 ± 8.7

0.78

  1. Data are means ± SD or absolute counts. APACHE III, Acute Physiology and Chronic Health Evaluation III; BMI, body mass index; CIM, Critical illness myopathy; CIP, Critical illness polyneuropathy; CIPNM, Critical illness polyneuropathy and/or myopathy; IVIG, intravenous immunoglobulin; SOFA, Sequential Organ Failure Assessment score.